Fugerel
Fugerel Uses, Dosage, Side Effects, Food Interaction and all others data.
Fugerel is a nonsteroidal 'pure' antiandrogen which acts directly on the target tissues either by blocking androgen uptake or by inhibiting cytoplasmic and nuclear binding of androgen.
Fugerel is a nonsteroidal antiandrogen. In animal studies, flutamide demonstrates potent antiandrogenic effects. It exerts its antiandrogenic action by inhibiting androgen uptake and/or by inhibiting nuclear binding of androgen in target tissues or both. Prostatic carcinoma is known to be androgen-sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen, e.g. castration. Elevations of plasma testosterone and estradiol levels have been noted following flutamide administration.
Trade Name | Fugerel |
Availability | Prescription only |
Generic | Flutamide |
Flutamide Other Names | Flutamid, Flutamida, Flutamide, Flutamidum, NFBA, Niftolid, Niftolide |
Related Drugs | spironolactone, estradiol, Premarin, Aldactone, Xtandi, Casodex, Zytiga, Lynparza, Vaniqa, Eulexin |
Type | |
Formula | C11H11F3N2O3 |
Weight | Average: 276.2118 Monoisotopic: 276.072176843 |
Protein binding | 94-96% |
Groups | Approved, Investigational |
Therapeutic Class | Hormonal Chemotherapy |
Manufacturer | |
Available Country | Bangladesh, China, Hong Kong, Indonesia, Philippines, Taiwan |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Fugerel is used for use in combination with LHRH agonists for the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate.
Stage B2-C Prostatic Carcinoma: Treatment with Fugerel and the LHRH agonist should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy.
Stage D2 Metastatic Carcinoma: To achieve benefit from treatment, Fugerel should be initiated with the LHRH agonist and continued until progression.
Fugerel is also used to associated treatment for these conditions: Acne Vulgaris, C Prostatic Carcinoma, Idiopathic Hirsutism, Stage B2 Prostatic Carcinoma, Stage D2 Prostatic carcinoma
How Fugerel works
Fugerel is a nonsteroidal antiandrogen that blocks the action of both endogenous and exogenous testosterone by binding to the androgen receptor. In addition Fugerel is a potent inhibitor of testosterone-stimulated prostatic DNA synthesis. Moreover, it is capable of inhibiting prostatic nuclear uptake of androgen.
Dosage
Fugerel dosage
Oral (Adult)-
Palliative treatment of prostatic carcinoma: 250 mg tid preferably at least 3 days before gonadorelin analogue treatment. May be taken with or without food.
Side Effects
Hot flushes, loss of libido, impotence, gynaecomastia, nausea, vomiting, diarrhoea, increased appetite, sleep disturbances, skin reactions, anaemias, headache, dizziness, malaise, anxiety, hypertension, gastric and chest pain, oedema, blurred vision, hepatitis, jaundice, rash, thirst, pruritus, SLE-like syndrome, drowsiness, confusion, depression, nervousness.
Toxicity
In animal studies with flutamide alone, signs of overdose included hypoactivity, piloerection, slow respiration, ataxia, and/or lacrimation, anorexia, tranquilization, emesis, and methemoglobinemia.
Precaution
Perform liver function tests before starting treatment and at regular intervals. Treatment is not recommended in patients whose ALT values exceed twice the upper limit of normal. Regular assessment of prostate specific antigen level may help to monitor disease progression. Advise patient against discontinuing drug on their own. Exercise caution in patients with cardiac disease.
Interaction
Increased prothrombin time in patients on long-term warfarin treatment.
Food Interaction
- Take with or without food. The absorption is unaffected by food.
Fugerel Drug Interaction
Major: sotalol, sotalolModerate: lithium, lithiumUnknown: amoxicillin / clavulanate, amoxicillin / clavulanate, duloxetine, duloxetine, heparin, heparin, leuprolide, leuprolide, metoprolol, metoprolol, acetaminophen, acetaminophen, vitamin a topical, vitamin a topical, bioflavonoids, bioflavonoids
Fugerel Disease Interaction
Elimination Route
Rapidly and completely absorbed.
Half Life
The plasma half-life for the alpha-hydroxylated metabolite of flutamide (an active metabolite) is approximately 6 hours.
Elimination Route
Fugerel and its metabolites are excreted mainly in the urine with only 4.2% of a single dose excreted in the feces over 72 hours.
Pregnancy & Breastfeeding use
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).
Contraindication
Hypersensitivity, severe hepatic impairment, pregnancy and lactation.
Storage Condition
Store at 25° C.
Innovators Monograph
You find simplified version here Fugerel
Fugerel contains Flutamide see full prescribing information from innovator Fugerel Monograph, Fugerel MSDS, Fugerel FDA label